JPRN-UMIN000007579已完成未知
Investigation of the incidence, severity, and treatment of dabigatran-related dyspepsia symptoms in patients with non-valvular atrial fibrillation (NVAF) - Dabigatran Dyspepsia Dialogue
Committee on Proper Use of Anticoagulant Therapies0 个研究点目标入组 500 人开始时间: 2012年3月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who meet any of the following criteria will be excluded from the study: 1. Have a history of hypersensitivity to any ingredients of the dabigatran preparation 2. Undergoing dialysis or have severe renal disorder (creatinine clearance < 30 mL/min*1) 3. Have hemorrhagic symptoms, hemorrhagic diathesis, or hemostatic disturbance 4. Have any organic lesion posing a clinically significant risk for bleeding (including onset of hemorrhagic stroke within the past 6 months) 5. Have a spinal/epidural catheter in place 6. Receiving (oral) itraconazole 7. Have undergone surgery for upper gastrointestinal tract (e.g., esophageal, gastric) resection or vagotomy 8. Have any organic disease confirmed by upper gastrointestinal endoscopy or X-ray performed within one year prior to the consent 9. Women with established or possible pregnancy, nursing mothers, or women who desire to become pregnant during the study participation 10. Other patients judged by the attending physician to be inappropriate as subjects Patients who meet any of the following criteria will be excluded from Part 2 of the study: 1. Receiving proton pump inhibitors, H2 receptor antagonists, or rebamipide (Mucosta) 2. Have a history of hypersensitivity to any ingredients of the study drug for dyspepsia symptoms, thus precluding administration of the study treatment 3. Have severe renal disorder (creatinine clearance < 30 mL/min*1) 4. Have dyspepsia symptoms that are apparently due to causative factors other than dabigatran, such as overdrinking, overeating, abrupt stress, or concomitant medication 5. Have experienced upper gastrointestinal bleeding or gastric/duodenal ulcerative disease during Part 1 of the study 6. Have concurrent gastroesophageal reflux disease confirmed by endoscopy or X-ray performed during Part 1 of the study 7. Other patients judged by the attending physician to be inappropriate as subjects
研究者
相似试验
已完成
不适用
Evaluation of the prevalence, incidence and progression of bone erosions in rheumatoid arthritis (RA) by high-resolution peripheral quantitative computer tomography (HRpQCT) compared to standard imaging techniquesNL-OMON22023Maastricht University Medical Center90
已完成
不适用
Evaluation of the prevalence, incidence and progression of bone erosions in rheumatoid arthritis (RA) by high-resolution peripheral quantitative computer tomography (HRpQCT) compared to standard imaging techniquesrheumatoid arthritis (RA)10023213NL-OMON41257Medisch Universitair Ziekenhuis Maastricht90
进行中（未招募）
不适用
An Investigation Into the Prevalence, Cause and treatment of Unexplained Anamia in Diabetes - Anamia and DiabetesAnaemia in DiabetesEUCTR2005-003057-28-GBniversity Hospital Aintree NHS Trust
尚未招募
Unknown
Analysis of the incidence, severity and temporal evolution of motion sickness after using the Air Force Academy's T-2000, T-3000 and T-4000 flight simulatorsMotion SicknessRBR-3fmc62zniversidade da Força Aérea
尚未招募
1 期
Study to determine the ideal endotracheal tube cuff pressure with the least side effects associated with intubation like sore throat, hoarseness of voice and throat pain using a cuff pressure manometer.CTRI/2023/07/055551Venu varun sri krishna p